Merus N.V. (MRUS)
Largest Insider Buys in Sector
MRUS Stock Price History Chart
MRUS Stock Performance
About Merus N.V.
Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, …
Insider Activity of Merus N.V.
Over the last 12 months, insiders at Merus N.V. have bought $0 and sold $5.61M worth of Merus N.V. stock.
On average, over the past 5 years, insiders at Merus N.V. have bought $42.73M and sold $17.22M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 14,706 shares for transaction amount of $211,431 was made by Lundberg Sven Ante (President, CEO & PFO) on 2022‑11‑03.
List of Insider Buy and Sell Transactions, Merus N.V.
| 2024-08-21 | Sale | VP Controller, PAO | 2,500 0.0037% | $54.00 | $135,000 | -4.35% | ||
| 2024-06-27 | Sale | COO & GC | 10,000 0.0159% | $60.00 | $600,000 | 0.00% | ||
| 2024-06-17 | Sale | COO & GC | 62,000 0.0926% | $56.52 | $3.5M | -7.22% | ||
| 2024-06-12 | Sale | VP Controller, PAO | 7,300 0.0112% | $57.84 | $422,232 | -8.63% | ||
| 2024-06-10 | Sale | VP Controller, PAO | 1,000 0.0015% | $53.22 | $53,224 | -2.91% | ||
| 2024-06-04 | Sale | VP Controller, PAO | 6,000 0.0095% | $52.89 | $317,354 | +3.44% | ||
| 2023-12-19 | Sale | VP Controller, PAO | 115 0.0002% | $26.68 | $3,068 | +78.33% | ||
| 2023-12-15 | Sale | COO & GC | 22,386 0.0386% | $25.00 | $559,650 | +89.64% | ||
| 2023-12-08 | Sale | VP Controller, PAO | 250 0.0004% | $24.44 | $6,110 | +98.72% | ||
| 2023-12-01 | Sale | VP Controller, PAO | 575 0.001% | $24.58 | $14,134 | +88.02% | ||
| 2023-06-01 | Sale | VP Controller, PAO | 575 0.0012% | $21.48 | $12,351 | +16.96% | ||
| 2022-12-13 | Sale | VP Controller, PAO | 168 0.0004% | $13.85 | $2,327 | +56.10% | ||
| 2022-12-01 | Sale | VP Controller, PAO | 575 0.0015% | $15.35 | $8,826 | +38.99% | ||
| 2022-11-03 | President, CEO & PFO | 14,706 0.0358% | $14.38 | $211,431 | +33.54% | |||
| 2022-08-25 | Sale | VP Controller, PAO | 165 0.0004% | $24.33 | $4,014 | -17.55% | ||
| 2022-08-22 | President, CEO & PFO | 5,826 0.0127% | $22.92 | $133,558 | -12.40% | |||
| 2022-08-19 | President, CEO & PFO | 704 0.0015% | $22.99 | $16,187 | -13.55% | |||
| 2022-07-12 | President, CEO & PFO | 4,340 0.0092% | $22.97 | $99,685 | -14.69% | |||
| 2022-06-01 | Sale | VP Controller, PAO | 575 0.0013% | $18.31 | $10,528 | +5.86% | ||
| 2022-03-10 | Sale | EVP, GC and Head of Utrecht | 60,000 0.133% | $26.95 | $1.62M | -27.93% |
Insider Historical Profitability
| BVF PARTNERS L P/IL | 10 percent owner | 232747 0.34% | $44.98 | 12 | 3 | +25.67% |
| Lundberg Sven Ante | President, CEO & PFO | 40576 0.0593% | $44.98 | 4 | 0 | <0.0001% |
Institutional Investor Ownership
| Commodore Capital, LP | $196.33M | 6.47 | 4.36M | -8.16% | -$17.44M | 0.74 | |
| RTW Investments, LP | $185.05M | 6.1 | 4.11M | +73.13% | +$78.16M | 2.77 | |
| Deerfield Management | $119.3M | 3.93 | 2.65M | -12.27% | -$16.68M | 0.29 | |
| Federated Hermes | $101.26M | 3.34 | 2.25M | -38.17% | -$62.52M | 0.24 | |
| Samlyn Capital, LLC | $93.51M | 3.08 | 2.08M | -39.15% | -$60.15M | 1.64 |